A neurophysiological study of near infrared spectroscopy haemoencephalography neurofeedback treatment in Alzheimer's disease and related cognitive impairments

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43516338

Enrollment

Registered

2006-09-29

Start date

2005-10-01

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases: Alzheimer's disease Nervous System Diseases Alzheimer's disease

Interventions

Phase 1 - establish the neurofeedback protocols, monitor treatment effects and side effects and confirm the number of participants required for Phase 2. Phase 2 - baseline and post treatment fMRI o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Phase 1: 10 patients with AMCI and 10 with mild AD Phase 2: 12-15 patients in each group depending upon the results of phase 1 of the study

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Change in cognition and/or behaviour following treatment.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026